Syncope Time Frames for Adverse Events after Emergency Department Presentation : An Individual Patient Data Meta-Analysis
Background and Objectives: Knowledge of the incidence and time frames of the adverse events of patients presenting syncope at the ED is essential for developing effective management strategies. The aim of the present study was to perform a meta-analysis of the incidence and time frames of adverse events of syncope patients. Materials and Methods: We combined individual patients' data from prospective observational studies including adult patients who presented syncope at the ED. We assessed the pooled rate of adverse events at 24 h, 72 h, 7-10 days, 1 month and 1 year after ED evaluation. Results: We included nine studies that enrolled 12,269 patients. The mean age varied between 53 and 73 years, with 42% to 57% females. The pooled rate of adverse events was 5.1% (95% CI 3.4% to 7.7%) at 24 h, 7.0% (95% CI 4.9% to 9.9%) at 72 h, 8.4% (95% CI 6.2% to 11.3%) at 7-10 days, 10.3% (95% CI 7.8% to 13.3%) at 1 month and 21.3% (95% CI 15.8% to 28.0%) at 1 year. The pooled death rate was 0.2% (95% CI 0.1% to 0.5%) at 24 h, 0.3% (95% CI 0.1% to 0.7%) at 72 h, 0.5% (95% CI 0.3% to 0.9%) at 7-10 days, 1% (95% CI 0.6% to 1.7%) at 1 month and 5.9% (95% CI 4.5% to 7.7%) at 1 year. The most common adverse event was arrhythmia, for which its rate was 3.1% (95% CI 2.0% to 4.9%) at 24 h, 4.8% (95% CI 3.5% to 6.7%) at 72 h, 5.8% (95% CI 4.2% to 7.9%) at 7-10 days, 6.9% (95% CI 5.3% to 9.1%) at 1 month and 9.9% (95% CI 5.5% to 17) at 1 year. Ventricular arrhythmia was rare. Conclusions: The risk of death or life-threatening adverse event is rare in patients presenting syncope at the ED. The most common adverse events are brady and supraventricular arrhythmias, which occur during the first 3 days. Prolonged ECG monitoring in the ED in a short stay unit with ECG monitoring facilities may, therefore, be beneficial.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
---|---|
Enthalten in: |
Medicina (Kaunas, Lithuania) - 57(2021), 11 vom: 12. Nov. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Furlan, Ludovico [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adverse events |
---|
Anmerkungen: |
Date Completed 30.11.2021 Date Revised 30.11.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/medicina57111235 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM333705823 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM333705823 | ||
003 | DE-627 | ||
005 | 20231225222208.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/medicina57111235 |2 doi | |
028 | 5 | 2 | |a pubmed24n1112.xml |
035 | |a (DE-627)NLM333705823 | ||
035 | |a (NLM)34833453 | ||
035 | |a (PII)1235 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Furlan, Ludovico |e verfasserin |4 aut | |
245 | 1 | 0 | |a Syncope Time Frames for Adverse Events after Emergency Department Presentation |b An Individual Patient Data Meta-Analysis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.11.2021 | ||
500 | |a Date Revised 30.11.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Background and Objectives: Knowledge of the incidence and time frames of the adverse events of patients presenting syncope at the ED is essential for developing effective management strategies. The aim of the present study was to perform a meta-analysis of the incidence and time frames of adverse events of syncope patients. Materials and Methods: We combined individual patients' data from prospective observational studies including adult patients who presented syncope at the ED. We assessed the pooled rate of adverse events at 24 h, 72 h, 7-10 days, 1 month and 1 year after ED evaluation. Results: We included nine studies that enrolled 12,269 patients. The mean age varied between 53 and 73 years, with 42% to 57% females. The pooled rate of adverse events was 5.1% (95% CI 3.4% to 7.7%) at 24 h, 7.0% (95% CI 4.9% to 9.9%) at 72 h, 8.4% (95% CI 6.2% to 11.3%) at 7-10 days, 10.3% (95% CI 7.8% to 13.3%) at 1 month and 21.3% (95% CI 15.8% to 28.0%) at 1 year. The pooled death rate was 0.2% (95% CI 0.1% to 0.5%) at 24 h, 0.3% (95% CI 0.1% to 0.7%) at 72 h, 0.5% (95% CI 0.3% to 0.9%) at 7-10 days, 1% (95% CI 0.6% to 1.7%) at 1 month and 5.9% (95% CI 4.5% to 7.7%) at 1 year. The most common adverse event was arrhythmia, for which its rate was 3.1% (95% CI 2.0% to 4.9%) at 24 h, 4.8% (95% CI 3.5% to 6.7%) at 72 h, 5.8% (95% CI 4.2% to 7.9%) at 7-10 days, 6.9% (95% CI 5.3% to 9.1%) at 1 month and 9.9% (95% CI 5.5% to 17) at 1 year. Ventricular arrhythmia was rare. Conclusions: The risk of death or life-threatening adverse event is rare in patients presenting syncope at the ED. The most common adverse events are brady and supraventricular arrhythmias, which occur during the first 3 days. Prolonged ECG monitoring in the ED in a short stay unit with ECG monitoring facilities may, therefore, be beneficial | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a ECG monitoring | |
650 | 4 | |a adverse events | |
650 | 4 | |a arrhythmia | |
650 | 4 | |a emergency department | |
650 | 4 | |a individual patient data | |
650 | 4 | |a meta-analysis | |
650 | 4 | |a mortality | |
650 | 4 | |a outcomes | |
650 | 4 | |a syncope | |
700 | 1 | |a Trombetta, Lucia |e verfasserin |4 aut | |
700 | 1 | |a Casazza, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a Dipaola, Franca |e verfasserin |4 aut | |
700 | 1 | |a Furlan, Raffaello |e verfasserin |4 aut | |
700 | 1 | |a Marta, Chiara |e verfasserin |4 aut | |
700 | 1 | |a Numeroso, Filippo |e verfasserin |4 aut | |
700 | 1 | |a Pérez-Rodon, Jordi |e verfasserin |4 aut | |
700 | 1 | |a Quinn, James V |e verfasserin |4 aut | |
700 | 1 | |a Reed, Matthew J |e verfasserin |4 aut | |
700 | 1 | |a Sheldon, Robert S |e verfasserin |4 aut | |
700 | 1 | |a Shen, Win-Kuang |e verfasserin |4 aut | |
700 | 1 | |a Sun, Benjamin C |e verfasserin |4 aut | |
700 | 1 | |a Thiruganasambandamoorthy, Venkatesh |e verfasserin |4 aut | |
700 | 1 | |a Ungar, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Costantino, Giorgio |e verfasserin |4 aut | |
700 | 1 | |a Solbiati, Monica |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicina (Kaunas, Lithuania) |d 1998 |g 57(2021), 11 vom: 12. Nov. |w (DE-627)NLM093687583 |x 1648-9144 |7 nnns |
773 | 1 | 8 | |g volume:57 |g year:2021 |g number:11 |g day:12 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/medicina57111235 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 57 |j 2021 |e 11 |b 12 |c 11 |